research use only
Cat.No.S4646
| Related Targets | Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR |
|---|---|
| Other Glucocorticoid Receptor Inhibitors | Corticosterone AL082D06 (20S)-Protopanaxatriol Cortodoxone |
|
In vitro |
DMSO
: 100 mg/mL
(184.94 mM)
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 540.69 | Formula | C32H44O7 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 126544-47-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Alvesco, Omnaris, RPR251526, Zetonna | Smiles | CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6 | ||
| In vitro |
Ciclesonide is effectively taken up into human alveolar type II epithelial (A549) cells and metabolized to its pharmacologically active metabolite des-CIC and fatty acid conjugates of desCIC.
|
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01147224 | Completed | Asthma|Allergy |
AstraZeneca |
March 2010 | -- |
| NCT00793858 | Withdrawn | Allergic Rhinitis |
University of Chicago|Sumitomo Pharma America Inc. |
February 2009 | Phase 4 |
| NCT00826969 | Completed | Asthma |
AstraZeneca |
September 2008 | Phase 4 |
| NCT00458835 | Completed | Allergic Rhinitis |
Covis Pharma S.à.r.l. |
April 2007 | Phase 4 |
| NCT00367263 | Completed | Asthma |
Allergy & Asthma Medical Group & Research Center |
October 2006 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.